You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1925 Results
Regimen
Regimen
Cancer Type:
Gastrointestinal, 
Mesothelioma (Peritoneal)
Intent: Palliative
Jan 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
Exceptional Access Program
    idelalisib - For the treatment of relapsed chronic lymphocytic leukemia, in combination with rituximab, according to specific clinical criteria
New Drug Funding Program
    Rituximab (Biosimilar IV) - In Combination with Idelalisib - Relapsed Chronic Lymphocytic Leukemia
Nov 2023
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
ODB - General Benefit
  • prednisone
Apr 2016
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • buserelin
Oct 2016
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI)
Intent: Palliative
Jul 2019
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Drugs Used:
binimetinib (Unfunded),
encorafenib (Unfunded),
cetuximab (Unfunded)
Jul 2023
Regimen
Cancer Type:
Hematologic, 
Rare Diseases
Intent: Palliative
Jul 2021
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Aug 2023
Regimen
Intent: Adjuvant
Funding:
ODB - General Benefit
    anastrozole
Apr 2024
Regimen
Cancer Type:
Breast, 
Gynecologic, 
Endometrial
Intent: Palliative
Funding:
ODB - General Benefit
    anastrozole
Apr 2024
Regimen

Pages